HeadlineShine

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

CNBC ·First reported 2h ago

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled — Image: CNBC

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

Summary from CNBC

Read the full story on CNBC

React

Trending now

Sports4 sources·28m ago

Jack Campbell injury update: Latest after Lions LB hospitalized

2 sources·1h ago

Why some key races won't be decided on election night

More business

Business4 sources·10h ago

Binance sees $3.64 billion in net outflows as withdrawals resume after massive hack

Business3 sources·18h ago

Fake nuclear warnings in Ukraine as Moscow, Kyiv report separate cyberattacks on emergency apps

Business2 sources·13h ago

CNBC's The China Connection newsletter: Nvidia's humanoid push relies on China-made robot hands

Business4 sources·12h ago

Trump called out Big Oil profits. Here’s how much their refining earnings have surged since

BusinessCNBC·12m ago

Yum Brands earnings beat estimates, but cyclospora outbreak weighs on Taco Bell

BusinessCNBC·13m ago

Pfizer hikes full-year outlook, taps company veteran as new CFO

Top stories in the United States

6 sources·11h ago

Trump Administration Asks Supreme Court to Intervene in California Ballot Case

Sports3 sources·3h ago

Every NHL ‘Hometown Remix’ jersey, ranked

Entertainment2 sources·2h ago

British Independent Film Awards: ‘Elsinore’ Leads Nominations With 12

Sports2 sources·3m ago

Ohio vs. Akron prediction, odds, time: Week 10 Tuesday MACtion college football picks from proven model

6 sources·17h ago

Judge tosses DOJ case against ex-FBI officials accused of lying about Hunter Biden probe: Reports

8 sources·3h ago

Rep. Haley Stevens endorses GOP candidate Mike Rogers in Michigan Senate race